Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma

Abstract Background: Many children with severe persistent allergic (IgE-mediated) asthma remain inadequately controlled despite treatment with high-dose inhaled corticosteroids (ICS) plus a long-acting β2-agonist (LABA). Research and design methods: This pre-specified analysis of a randomized, doubl...

Full description

Saved in:
Bibliographic Details
Published in:Current medical research and opinion 2010-06, Vol.26 (6), p.1285-1293
Main Authors: Kulus, M., Hébert, J., Garcia, E., Fowler Taylor, A., Fernandez Vidaurre, C., Blogg, M.
Format: Article
Language:English
Subjects:
Anti-Allergic Agents - adverse effects
Anti-Allergic Agents - pharmacology
Anti-Allergic Agents - therapeutic use
Antibodies, Anti-Idiotypic
Antibodies, Monoclonal - adverse effects
Antibodies, Monoclonal - pharmacology
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized
Asthma
Asthma - drug therapy
Asthma - immunology
Child
Double-Blind Method
Efficacy
Female
Humans
Immunoglobulin E - immunology
Male
Omalizumab
Paediatrics
Safety
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background: Many children with severe persistent allergic (IgE-mediated) asthma remain inadequately controlled despite treatment with high-dose inhaled corticosteroids (ICS) plus a long-acting β2-agonist (LABA). Research and design methods: This pre-specified analysis of a randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of omalizumab in children (6-
ISSN:0300-7995
1473-4877
DOI:10.1185/03007991003771338